Day One
The Goals of the Hatch-Waxman Act as Seen from 2024
Bob Armitage, Intellectual Property Consultant
Alfred B. Engelberg
Katherine Strandburg, Engelberg Center on Innovation Law & Policy, NYU School of Law (moderator)
An Empirical Evaluation of the Hatch-Waxman Act
Scott Hemphill, Engelberg Center on Innovation Law & Policy, NYU School of Law
Bhaven Sampat, Arizona State University
Margaret K. Kyle, MINES ParisTech (Ecole des Mines) (commentator)
Extending the Hatch-Waxman Act Model
Michael Frakes, Duke University School of Law
Emily Marden, Sidley Austin LLP
Nicholson Price, The University of Michigan Law School
S. Sean Tu, West Virginia University College of Law
Melissa Wasserman, The University of Texas School of Law
Bruce Wexler, Paul Hastings LLP (moderator)
Fireside Chat
Commissioner Rebecca Kelly Slaughter, Federal Trade Commission
Daniel Francis, NYU School of Law
Protecting the Hatch-Waxman Act from Anticompetitive Gaming
Anisha Dasgupta, Federal Trade Commission
Henry Hadad, Bristol-Myers Squibb
Steve Shadowen, Hilliard Shadowen LLP
Eric Stock, Gibson, Dunn & Crutcher LLP
Scott Hemphill, Engelberg Center on Innovation Law & Policy, NYU School of Law (moderator)
The Neglected Hatch-Waxman Act Goal of Data Transparency
Rebecca Eisenberg, The University of Michigan Law School
Richard F. Kingham, Covington & Burling LLP
Reshma Ramachandran, Yale School of Medicine
Chris Morten, Columbia Law School (moderator)
Day Two
Drug Price Negotiations
Richard Epstein, NYU School of Law
Erika Lietzan, University of Missouri School of Law
Lisa Larrimore Ouellette, Stanford Law School
Steve Pearson, Institute for Clinical and Economic Review (ICER)
Rachel Sachs, Washington University in St. Louis School of Law
Daniel Hemel, NYU School of Law (moderator)
March-in Rights and § 1498
David J. Kappos, Cravath, Swaine, & Moore LLP
Aaron Kesselheim, Brigham and Women’s Hospital/Harvard Medical School
Rochelle Dreyfuss, Engelberg Center on Innovation Law & Policy, NYU School of Law (moderator)
What’s Next?
Donald Beers, Office of Chief Counsel of the Food and Drug Administration (FDA) (retired)
Alfred B. Engelberg
Abbe Gluck, Yale Law School
Arti Rai, Duke University School of Law
Ameet Sarpatwari, Harvard Medical School
Michael Weinberg, Engelberg Center on Innovation Law & Policy, NYU School of Law (moderator)
This event will not be livestreamed. However, we will publish the audio file on our podcast page here for your enjoyment a week after the event.
This event has been approved for 12 New York State CLE credits in the category of Areas of Professional Practice. The credit is both transitional and non-transitional; it is appropriate for both experienced and newly admitted attorneys.
Click here for our CLE reading materials.
This event is governed by the Engelberg Center’s Code of Conduct and NYU’s COVID policies.
